David M. Rubin, Ph.D., is a Managing Director focused on digital health and precision medicine mainly focused in oncology and has spent more than 30 years in the healthcare industry. Before joining the GHI team, Dr. Rubin lead a portfolio management group in MSD Research Labs, where he facilitated the development of franchise strategies and analysis of portfolio valuations. David joined MSD from Cognia Corporation, a venture-backed international healthcare R&D software company, where he was CEO. Previously, Dr. Rubin was a management consultant at The Wilkerson Group/IBM Global Services. Dr. Rubin holds a Ph.D. from Temple University in Molecular Biology and a B.A. from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University.